Navigation Links
Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
Date:9/4/2012

IRVINE, Calif., Sept. 4, 2012 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal fourth quarter and full-year ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c)

Pro-Dex, Inc. (the "Company") reported a loss from continuing operations of $452,000, or $0.14 per diluted share, for the quarter ended June 30, 2012 compared to income from continuing operations of $1.0 million, or $0.31 per diluted share, in the same period of fiscal 2011.  The net loss for the fourth quarter of fiscal 2012 was $545,000 or $0.17 per diluted share, compared to net income of $1.0 million or $0.31 per diluted share in the fourth quarter of fiscal 2011.  Sales for the quarter ended June 30, 2012 decreased 46% to $3.7 million from $6.8 million for the corresponding quarter in 2011, and decreased 28% to $17.3 million from $24.0 million for the fiscal years ended June 30, 2012 and 2011, respectively.  For fiscal year 2012, the net loss was $876,000, or $0.27 per diluted share, as compared to net income of $2.6 million, or $0.80 per diluted share for fiscal year 2011.  As the Company has disclosed previously, the decrease in sales and the resulting net losses were primarily the result of the continuation of a reduction in purchases of the Company's medical device products by its largest customer. The results from continuing operations for the 2012 and 2011 periods exclude the results of the Company's former Astromec product line, which was sold in February 2012 as previously announced. 

Gross profit for the quarter ended June 30, 2012 was $858,000, or 23%, compared to gross profit of $2.9 million, or 43%, for the year-ago period.  For fiscal year 2012, gross profit was $5.4 million, or 31%, compared to $10.1 million and 42%, respectively, for fiscal year 2011. These decreases resulted primarily from the year-over-year decrease in sales and a commensurate change in sales mix to products with lower gross margins, and from reductions in manufacturing efficiencies due to the lower sales volume.

Operating expenses, which include selling, general and administrative, and research and development expenses, for the fourth fiscal quarter of 2012 decreased 12% to $1.6 million from $1.8 million in the prior year's fourth quarter.  The decrease was primarily attributable to lower performance-based bonuses having been accrued in 2012, relative to 2011.
For the year ended June 30, 2012, operating expenses were relatively unchanged from fiscal 2011, increasing by $118,000, or 2%.  Underlying the absence of a year-over-year change was a decrease in employee compensation, including the aforementioned lower bonuses, and other operating expense cuts, offset by costs of $485,000 incurred of severance costs associated with the replacement of our CEO and Vice President of Sales, and the two previously announced reductions in force.

The pre-tax loss from continuing operations was $707,000 for the quarter, compared to pre-tax income from continuing operations of $1.1 million in the corresponding 2011 period.  For the year ended June 30, 2012, the pre-tax loss from continuing operations was $1.4 million, compared to pre-tax income of $3.3 million in fiscal year 2011.

The Company also announced that, on August 30, 2012, it notified the bank with which it has maintained a credit facility, of the Company's intent to terminate that facility and repay in full, on or before September 30, 2012, the $685,000 currently outstanding balance of its term loan with the bank.

Michael J. Berthelot, the Company's President and Chief Executive Officer, commented, "The results we reported today for fiscal 2012 are consistent with those we previewed a few weeks ago.  As we near the end of the first quarter of fiscal 2013 we continue to make progress on all four of our key strategic programs.  Our sales effort has identified a number of possible new client relationships which we continue to develop and we see exciting possibilities ahead.  Our newly quoted lead times are coming down and we believe we will meet or exceed our customers' expectations as to delivery dates.  Our cost control efforts are bearing fruit as our downsized workforce has stepped up to the tasks at hand and increased productivity.  Our programs for innovation and quality improvement have identified key strategic objectives and are pursuing their implementation.  At the end of the first quarter we will provide a more detailed report on our progress and an update as to our outlook for fiscal 2013."

Mr. Berthelot continued, "As we have previously pointed out, because we reported a loss for the fiscal year ended June 30, 2012, we were in violation of one of our financial covenants under our bank credit facility.  Following discussions with our bank, and recognizing that we have not used the line of credit provided in the facility and that the highest return on some of the cash we hold would be realized by retiring in full our term loan, we have advised our lender that we wish to terminate our line of credit immediately and will retire our term loan in full not later than September 30, 2012.  This action will save us approximately $15,000 in interest in fiscal 2013 and $8,000 in 2014 while eliminating administrative time associated with the unused line of credit.  The cash balances we currently enjoy are, we believe, more than adequate to provide the necessary cash resources we may need to pursue our programs for fiscal 2013.  We may seek to establish a new, smaller line of credit in the future."  

Teleconference Information:Investors and analysts are invited to listen to a broadcast review of the Company's fiscal 2012 fourth quarter and full-year financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company's website at www.pro-dex.com.  The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Eastern Time) on September 19, 2012 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering account number 286 and conference I.D. number 399844.  An online archive of the broadcast will be available on the Company's website www.pro-dex.com for a period of 365 days.

About Pro-Dex, Inc.:Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its OMS division designs and manufactures embedded motion control systems serving the medical, dental, semi-conductor and scientific research markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

 (tables follow)

 PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, 2012June 30, 2011ASSETSCurrent assets:Cash

$
4,112,000$  4,689,000Accounts receivable, net of allowance for doubtful accounts of $16,000 and $7,000 at June 30, 2012 and 2011, respectively

1,581,0003,128,000Other current receivables

123,00012,000Inventories

2,791,0003,703,000Prepaid expenses

172,000145,000Income taxes receivable

609,000--Deferred income taxes

109,000163,000Total current assets

9,497,00011,840,000Property, plant, equipment and leasehold improvements, net

2,539,0003,661,000Real estate held for sale

733,000--Other assets

53,00060,000Total assets

$
2,822,000$ 15,561,000LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
33,000$  1,207,000Accrued expenses

1,425,0002,379,000Income taxes payable

47,00078,000Current portion of bank term loan

774,000357,000Total current liabilities

2,879,0004,021,000Non-current liabilities:Bank term loan

--774,000Deferred income taxes

109,000163,000Deferred rent

284,000279,000Total non-current liabilities

393,0001,216,000Total liabilities

3,272,0005,237,000Commitments and contingenciesShareholders' equity:Common shares; no par value; 50,000,000 shares authorized; 3,272,350 shares issued and outstanding at June 30, 2012 and 2011

16,846,00016,744,000Accumulated deficit

(7,296,000)(6,420,000)Total shareholders' equity

9,550,00010,324,000Total liabilities and shareholders' equity

$
2,822,000$ 15,561,000 PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For The Years
Ended June 30,20122011Net sales

$17,257,000$ 24,060,000Cost of sales

11,841,00013,919,000Gross profit

5,416,00010,141,000Operating expenses:Selling expenses

1,531,0001,600,000General and administrative expenses

3,182,0003,174,000Research and development costs

2,068,0001,889,000Total operating expenses

6,781,0006,663,000Income (loss) from continuing operations before items below

(1,365,000)3,478,000Other expense:Interest expense

36,000148,000Total other expense

36,000148,000Income (loss) from continuing operations before provision for income taxes

(1,401,000)3,330,000Provision for (benefit from) income taxes

(441,000)530,000Income (loss) from continuing operations

(960,000)2,800,000Income (loss) from discontinued operations, net of (benefit) from income taxes of $(146,000) in 2012 and $(74,000) in 2011

84,000(160,000)Net income (loss)

$ (876,000)$ 2,640,000Per share data:Income (loss) from continuing operationsBasic

$
(0.29)$
.86Diluted

$
(0.29)$
.85Income (loss) from discontinued operationsBasic

$
.02$
(0.05)Diluted

$
.02$
(0.05)Net income (loss)Basic

$
(0.27)$
.81Diluted

$
(0.27)$
.80Weighted average shares outstanding — basic

3,272,3503,264,936Weighted average shares outstanding — diluted

3,272,3503,287,415 PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS  For The Years Ended
June 30,20122011Cash flows from operating activities:Net income (loss)

$ (876,000)$ 2,640,000Adjustments to reconcile net income (loss) to net cash provided by operating activities:Depreciation and amortization

647,000697,000Allowance for doubtful accounts

9,000(18,000)Share-based compensation

108,00043,000Changes in:Accounts receivable and other receivables

1,428,000(418,000)Inventories

912,000(475,000)Prepaid expenses

(26,000)29,000Other assets

7,00018,000Accounts payable and accrued expenses

(1,523,000)383,000Income taxes receivable and payable

(641,000)(1,000)Net cash provided by operating activities

45,0002,898,000Cash flows from investing activities:Purchase of equipment

(341,000)(265,000)Proceeds from sale of equipment

82,000--Net cash used in investing activities

(259,000)(265,000)Cash flows from financing activities:Principal payments on bank term loan

(357,000)(236,000)Principal payments on mortgage

--(1,528,000)Repurchase of stock options

(6,000)--Proceeds from exercise of stock options

--26,000Net cash used in financing activities

(363,000)(1,738,000)Net increase (decrease) in cash

(577,000)895,000Cash, beginning of year

4,689,0003,794,000Cash, end of year

$ 4,112,000$ 4,689,000Supplemental InformationCash paid for interest

$
37,000$
48,000Cash paid for income taxes

$
56,000$
456,000 


'/>"/>
SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
2. Pro-Dex, Inc. Announces Update Conference Call and Webcast
3. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
4. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015
7. International Isotopes Inc. Announces Nuclear Regulatory Commission Approval Of The Final Environmental Impact Statement For The Planned Depleted Uranium De-Conversion And Fluorine Extraction Processing Facility
8. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
9. Shield HealthCare Announces 12th Annual Caregiver Story Contest
10. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
11. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... , Feb. 9, 2016 Mast Therapeutics, ... clinical-stage therapies for sickle cell disease and heart failure, today ... and warrants to purchase common stock in an underwritten public ... and there can be no assurance as to whether or ... actual size or terms of the offering.   ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics this week announced the launch of the ... , “Our goal was to develop a product from the ground up that ... ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The Conform series ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost increases ... D a decade ago, according to The Senior Citizens League (TSCL). ... are coping with rapidly rising costs. “The implications are chilling, particularly for people ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Body Specialists are delighted to welcome a new addition to their growing practice. ... Body Specialists as a nurse practitioner performing cosmetic procedures including injectables, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
Breaking Medicine News(10 mins):